EMA Expands Safety Guidance for Developing Anticancer Drugs

Clinical Trials Advisor
A A
The European Medicines Agency adopted the fifth revision of its substantive guideline covering all stages of oncology drug development, expanding upon the previous version’s section on safety data.

To View This Article:

Login

Subscribe To Clinical Trials Advisor